TABLE 1.
Clinical characteristics of HCC patients between two groups divided by risk score.
| Low-risk score group (n = 6) | High-risk score group (n = 3) | p value | |
|---|---|---|---|
| Risk score | 0.1 (0.0) | 0.8 (0.1) | 0.00 |
| Gender (male/female) | 6/0 | 3/0 | 1.00 |
| Age (year) | 52.3 (5.5) | 58.3 (4.1) | 0.50 |
| Height (cm) | 172.5 (1.7) | 169.3 (4.7) | 0.45 |
| Weight (kg) | 70.5 (3.1) | 70.2 (5.1) | 0.95 |
| ASA stage (I/II) | 3/3 | 0/3 | 0.46 |
| Child-Pugh stage (I/II) | 6/0 | 0/3 | 0.01 |
| TNM stage (I/III) | 4/2 | 0/3 | 0.17 |
| Hypertension (Yes/No) | 4/2 | 3/0 | 0.50 |
| Hepatitis (Yes/No) | 6/0 | 3/0 | 1.00 |
| Cirrhosis (Yes/No) | 6/0 | 3/0 | 1.00 |
| PVTT (Yes/No) | 2/4 | 3/0 | 0.17 |
| Artery invasion (Yes/No) | 0/6 | 3/0 | 0.01 |
| Primary HCC (Yes/No) | 6/0 | 3/0 | 1.00 |
| Tumor number (Single/Multiple) | 6/0 | 2/1 | 0.33 |
| Tumor size | 2.8 (0.6) | 9.0 (1.3) | 0.00 |
| ALT (U/L) | 56.8 (25.7) | 23.0 (5.5) | 0.40 |
| AST (U/L) | 45.5 (14.4) | 24.7 (8.2) | 0.37 |
| TBiL (mmol/L) | 14.9 (2.1) | 14.5 (0.9) | 0.89 |
| ALB (g/L) | 43.5 (0.9) | 41.1 (2.5) | 0.30 |
| AFP (ng/ml) | 56.5 (38.8) | 139.2 (134.9) | 0.61 |
| INR | 1.0 (0.0) | 1.1 (0.1) | 0.16 |
| Cr (μmol/L) | 56.2 (5.1) | 80.7 (4.3) | 0.02 |
| White blood cell (109/L) | 5.6 (0.7) | 5.4 (0.5) | 0.89 |
| HB (g/L) | 132.0 (7.9) | 146.0 (6.4) | 0.29 |
| PLT (109/L) | 214.5 (50.8) | 146.0 (15.3) | 0.39 |
Variables are shown as “mean (SD)”. HCC, Hepatocellular carcinoma; ASA, American Society of Anesthesiologists; TNM, Clinicopathological stage; PVTT, portal vein tumor thrombus; ALT, Alanine transaminase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, serum albumin; AFP, alpha-fetoprotein; INR, International Normalized Ratio; Cr, creatinine; HB, hemoglobin; PLT, platelets; SD, standard deviation.